C4 Therapeutics, Inc. (NASDAQ:CCCC) Given Consensus Rating of “Moderate Buy” by Brokerages

C4 Therapeutics, Inc. (NASDAQ:CCCC) has been given an average rating of “Moderate Buy” by the seven analysts that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $7.75.

CCCC has been the topic of a number of recent research reports. TD Cowen reiterated a “buy” rating on shares of C4 Therapeutics in a report on Thursday, February 26th. Wall Street Zen raised shares of C4 Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Saturday, February 28th. Barclays lifted their price target on shares of C4 Therapeutics from $5.00 to $7.00 and gave the company an “overweight” rating in a research note on Thursday, February 26th. boosted their price target on shares of C4 Therapeutics from $20.00 to $30.00 and gave the stock a “buy” rating in a research report on Monday, February 23rd. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of C4 Therapeutics in a research note on Wednesday, January 21st.

C4 Therapeutics Stock Performance

NASDAQ:CCCC opened at $2.41 on Monday. The stock has a 50-day simple moving average of $2.38 and a 200 day simple moving average of $2.39. C4 Therapeutics has a 52-week low of $1.09 and a 52-week high of $3.82. The company has a market cap of $235.17 million, a PE ratio of -1.77 and a beta of 2.85.

C4 Therapeutics (NASDAQ:CCCC) last released its earnings results on Thursday, February 26th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.43) by $0.25. C4 Therapeutics had a negative return on equity of 53.83% and a negative net margin of 292.08%.The firm had revenue of $11.02 million for the quarter, compared to analysts’ expectations of $4.48 million. On average, research analysts predict that C4 Therapeutics will post -1.52 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Virtu Financial LLC bought a new position in C4 Therapeutics in the fourth quarter valued at approximately $39,000. Invesco Ltd. raised its stake in shares of C4 Therapeutics by 39.9% during the 4th quarter. Invesco Ltd. now owns 268,350 shares of the company’s stock worth $513,000 after purchasing an additional 76,530 shares in the last quarter. Quadrature Capital Ltd bought a new stake in shares of C4 Therapeutics during the 4th quarter worth approximately $254,000. Man Group plc boosted its holdings in shares of C4 Therapeutics by 72.9% in the 4th quarter. Man Group plc now owns 156,098 shares of the company’s stock valued at $298,000 after buying an additional 65,820 shares during the last quarter. Finally, Engineers Gate Manager LP boosted its holdings in shares of C4 Therapeutics by 49.9% in the 4th quarter. Engineers Gate Manager LP now owns 24,416 shares of the company’s stock valued at $47,000 after buying an additional 8,130 shares during the last quarter. 78.81% of the stock is owned by institutional investors and hedge funds.

About C4 Therapeutics

C4 Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted protein degraders. Utilizing its proprietary Controlled Inducible Degradation (CiD) platform, the company seeks to eliminate disease-causing proteins by harnessing the body’s natural protein disposal machinery. This approach aims to address a wide range of oncology and immuno-oncology indications by targeting proteins that have historically been difficult to inhibit with traditional small molecules or antibodies.

The company’s pipeline includes multiple small-molecule degrader candidates advancing through preclinical and clinical stages.